Navigation Links
General Wesley Clark Joins Immtech as Consulting Strategic Advisor

NEW YORK, Sept. 10 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) is pleased to announce today that General Wesley Clark (ret.) has joined Immtech as a strategic advisor. General Clark will provide counsel to Immtech's management team as the Company develops its drug programs targeting various global health challenges, including malaria prevention and treatment.

General Clark is one of the country's most distinguished retired military officers and a respected international voice in public affairs and diplomacy. He served as NATO Supreme Allied Commander from 1997 to 2000 and commanded troops in the campaign to end the Kosovo War, and he played a pivotal role in negotiating the Dayton Peace Accords to end the war in Bosnia.

"I am truly impressed by the private/public partnerships that Immtech has created as part of its effective business model to develop new treatments for global diseases," said General Clark. "I look forward to working closely with Immtech's leadership as the Company advances Immtech's promising drug pipeline."

General Clark served for 33 years with the United States Army, rising to the rank of 4-star general. He is a recipient of the Silver Star, Bronze Star, and Purple Heart, along with honorary Knighthoods from the British and Dutch governments. He was also made a commander of the French Legion of Honor, and in 2000 he was awarded the Presidential Medal of Freedom, the nation's highest civilian honor.

"We are honored to have General Clark join Immtech in this strategic advisory role," said Eric L. Sorkin, Immtech's Chairman and Chief Executive Officer. "General Clark will enhance Immtech's strategic work with international companies, foundations and governments. Few people have a better understanding of international cooperation, and we stand to benefit greatly from General Clark's expertise."

General Clark graduated top of his class from the United States Military Academy at West Point, and he holds a Master's Degree from Oxford University where he was a Rhodes Scholar. He was a U.S. presidential candidate in the 2004 election and is presently Chairman and CEO of Wesley K. Clark & Associates, a strategic advisory and consulting firm. He is also Chairman of Rodman and Renshaw, a New York based investment bank.

Immtech's first oral drug candidate, pafuramidine maleate, is currently in two phase II clinical trials for treatment and prevention of malaria. Each year malaria kills over one million people. It is also a significant threat to 125 million people who travel annually from developed countries to malaria endemic areas. Pafuramidine is also in two pivotal Phase III trials targeting the treatment of Pneumocystis pneumonia (PCP), a severe form of fungal infection in the lungs, and African sleeping sickness.

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. is focused on developing and commercializing drugs to treat infectious diseases. Immtech has advanced clinical programs that include new treatments for Pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (African sleeping sickness), and a well defined, expanding library of compounds targeting Hepatitis C, fungal infections, and bacterial infections. Immtech holds exclusive worldwide licenses to certain patents, patent applications and technology for products derived from a proprietary pharmaceutical platform. For additional information, please go to

"Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.'s business, including the future prospects for PCP, which are not historical facts are "forward- looking statements" that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" in Immtech's annual report on Form 10-K for the year ended March 31, 2007 and in its other SEC filings and include: (i) Immtech's ability to develop commercially viable products; (ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to retain key personnel; (iv) the ability of Immtech's scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech's ability to obtain regulatory approval of its drug candidate, including PCP; (vii) the success of Immtech's clinical trials; (viii) dependence upon and contractual relationship with partners; (ix) Immtech's ability to manufacture or to have a third party manufacture its drug candidate at a reasonable cost; (x) Immtech's ability to protect its intellectual property; (xi) competition and alternative technologies; (xii) Immtech's ability to obtain reimbursement from third party payers for any product it commercializes; and (xiii) potential exposure to significant product liability.

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Suggest Cymbalta Improved Functioning in Patients with Generalized Anxiety Disorder
2. Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry
3. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
4. FDA Announces Change of Location Notice for Upcoming Advisory Committee Meeting
5. Media Advisory: ACC Updated Schedule
Post Your Comments:
(Date:10/13/2015)... , Oct. 13, 2015  Data Science Automation (DSA), ... opening of a new branch office in the ... DSA,s presence in Europe . The decision ... increasing demand for local support of customers in the medical ... Ph.D., DSA,s UK Branch Manager. "We have had tremendous success ...
(Date:10/13/2015)... DIEGO , Oct. 13, 2015  Nanomedical ... for use in research and diagnostics, announces the ... $1.6 million led by Serra Ventures. ... mission is providing low-cost, easy-to-use monitoring and diagnostic ... health decisions. The funding round will enable the ...
(Date:10/13/2015)... PARK, Md. , Oct. 13, 2015 Attracting ... is the biggest key to growing Baltimore ... a report released today by the Maryland Technology Enterprise ... has many of the pieces in place to support innovation ... Connolly , director of Mtech Baltimore. "This study is important ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 13, 2015 , ... According to an article published October 5th ... who successfully lose weight with a bariatric procedure are much less likely to develop ... notes that anywhere from 40 to 50 percent of all endometrial cancer cases are ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... In an ... utility costs were 36 percent lower per square foot than in 2009. The Williamsport ... cost of heating and cooling has decreased by eight percent. , According to ...
(Date:10/13/2015)... ... ... A child without a healthy mouth is much more likely to have an ... has joined with Global Dental Relief (GDR) to help bring dental care ... SmileCareClub will donate one clinic visit to a child in Kenya. , “When SmileCareClub ...
(Date:10/13/2015)... ... 13, 2015 , ... Scientists in Seattle and Vancouver compared the diagnostic value ... without mesothelioma. Surviving Mesothelioma has just posted an article on the new research. ... Seattle and the University of British Columbia found that certain genetic alterations were seen ...
(Date:10/13/2015)... , ... October 13, 2015 , ... World Patent ... Snow Blanket, a snow melting invention that helps people in clearing snow away from ... will continue to grow at 3.8% per year," says Scott Cooper, CEO and Creative ...
Breaking Medicine News(10 mins):